biostudies-literatureJohnson SPCancer Research UKEuropean Research CouncilMedical Research CouncilNational Institute for Health Research (NIHR)Engineering and Physical Sciences Research Council7436-7447https://www.ebi.ac.uk/biostudies/studies/S-EPMC7611302biostudies-literatureUnknown25(24)<h4>Purpose</h4>Photoacoustic imaging (PAI) is a novel noninvasive and nonionizing imaging technique that allows longitudinal imaging of tumor vasculature <i>in vivo</i> and monitoring of response to therapy, especially for vascular targeted chemotherapy agents. In this study, we used a novel high-resolution all-optical PAI scanner to observe the pharmacodynamic response to the vascular-disrupting agent OXi4503.<h4>Experimental design</h4>Two models of colorectal carcinoma (SW1222 and LS174T) that possess differing pathophysiologic vascularization were established as subcutaneous tumors in mice. Monitoring of response was performed over a 16-day "regrowth" period following treatment at 40 mg/kg, and at day 2 for a "dose response" study at 40 mg/kg, 10 mg/kg, 1 mg/kg, and sham dose.<h4>ResuClinical cancer research : an official journal of the American Association for Cancer ResearchLongitudinal Photoacoustic Imaging of the Pharmacodynamic Effect of Vascular Targeted Therapy on Tumors.PMC7611302G1001497A103311646321030741149C1519/A10331Beard PPedley RBLythgoe MFJohnson SPOgunlade OfalseLongitudinal Photoacoustic Imaging of the Pharmacodynamic Effect of Vascular Targeted Therapy on Tumors.<h4>Purpose</h4>Photoacoustic imaging (PAI) is a novel noninvasive and nonionizing imaging technique that allows longitudinal imaging of tumor vasculature <i>in vivo</i> and monitoring of response to therapy, especially for vascular targeted chemotherapy agents. In this study, we used a novel high-resolution all-optical PAI scanner to observe the pharmacodynamic response to the vascular-disrupting agent OXi4503.<h4>Experimental design</h4>Two models of colorectal carcinoma (SW1222 and LS174T) that possess differing pathophysiologic vascularization were established as subcutaneous tumors in mice. Monitoring of response was performed over a 16-day "regrowth" period following treatment at 40 mg/kg, and at day 2 for a "dose response" study at 40 mg/kg, 10 mg/kg, 1 mg/kg, and sham dose.<h4>Resu2019-01-01T00:00:00Z2019 Dec2026-04-30T03:10:33.615Z2022-02-10T21:40:15.754ZS-EPMC76113023155134910.1158/1078-0432.CCR-19-036010.1158/1078-0432.ccr-19-0360